BIOMAT Database Logo BIOMAT Database Logo

[Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance]. 2017

W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
Department of Pathology, Wannan Medical College Yijishan Hospital, Wuhu 241001, China.

Objective: To investigate the correlation between the expression of PD-1, PD-L1 and clinicopathologic parameters in triple negative breast carcinoma (TNBC). Methods: Samples from 151 patients with TNBC and 65 cases of other breast carcinomas (non-TNBC) were examined for PD-L1 and PD-1 expression by immunohistochemical staining on tissue microarray. Results: The expression of PD-L1 and PD-1 in the tumor cells and interstitial lymphocytes in TNBC was significantly (P<0.05)higher than that in non-TNBC.In TNBC, the expression rates of PD-L1 in the cancer nests and stroma were 16.6%(25/151) and 25.2%(38/151)respectively.The former was positively correlated with tumor histological grade and lymph node metastasis (P<0.05), and the latter only with tumor histological grade (P<0.05). The expression rate of PD-1 was 27.2% (41/151), and correlated with PD-L1 expression in stromal tumor-infiltrating lymphocytes (P<0.05). Conclusion: The expression of PD-L1 in TNBC is significantly correlated with high-grade histology, lymph node metastasis and PD-L1 expression in stromal tumor-infiltrating lymphocytes.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016246 Lymphocytes, Tumor-Infiltrating Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. Tumor Infiltrating Lymphocyte,Tumor-Derived Activated Cell,Tumor-Derived Activated Cells,Tumor-Infiltrating Lymphocyte,Tumor-Infiltrating Lymphocytes,Activated Cell, Tumor-Derived,Activated Cells, Tumor-Derived,Infiltrating Lymphocyte, Tumor,Infiltrating Lymphocytes, Tumor,Lymphocyte, Tumor Infiltrating,Lymphocyte, Tumor-Infiltrating,Lymphocytes, Tumor Infiltrating,Tumor Derived Activated Cell,Tumor Derived Activated Cells,Tumor Infiltrating Lymphocytes
D060787 Neoplasm Grading Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm. Gleason Grading,Gleason Score,Tumor Grading,Grading, Gleason,Grading, Neoplasm,Grading, Tumor,Score, Gleason
D060890 B7-H1 Antigen An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION. Antigens, CD274,PD-L1 Protein,Programmed Cell Death 1 Ligand 1 Protein,Programmed Death Ligand 1,B7-H1 Immune Costimulatory Protein,B7H1 Immune Costimulatory Protein,CD274 Antigen,PD-L1 Costimulatory Protein,Programmed Cell Death 1 Ligand 1,Antigen, B7-H1,Antigen, CD274,B7 H1 Antigen,B7 H1 Immune Costimulatory Protein,CD274 Antigens,Costimulatory Protein, PD-L1,PD L1 Costimulatory Protein,PD L1 Protein
D061026 Programmed Cell Death 1 Receptor An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE. PD-1 Protein,Programmed Cell Death 1 Protein,Programmed Cell Death Protein 1,Antigens, CD279,CD279 Antigen,PD-1 Receptor,PD1 Receptor,Antigen, CD279,CD279 Antigens,PD 1 Protein,PD 1 Receptor,Receptor, PD-1,Receptor, PD1
D064726 Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN. ER-Negative PR-Negative HER2-Negative Breast Cancer,ER-Negative PR-Negative HER2-Negative Breast Neoplasms,Triple Negative Breast Cancer,Triple-Negative Breast Cancer,Triple-Negative Breast Neoplasm,Breast Cancer, Triple-Negative,Breast Cancers, Triple-Negative,Breast Neoplasm, Triple-Negative,Breast Neoplasms, Triple-Negative,ER Negative PR Negative HER2 Negative Breast Cancer,ER Negative PR Negative HER2 Negative Breast Neoplasms,Triple Negative Breast Neoplasm,Triple-Negative Breast Cancers,Triple-Negative Breast Neoplasms

Related Publications

W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
PD-L1 expression in triple-negative breast cancer.
April 2014, Cancer immunology research,
W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
[Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
March 2022, Zhonghua zhong liu za zhi [Chinese journal of oncology],
W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer.
January 2022, BioMed research international,
W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance.
April 2024, Cancer research and treatment,
W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
[Evaluation of PD-L1 expression and intratumoral lymphocytic infiltration in triple-negative invasive breast carcinoma].
January 2024, Medicina,
W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
July 2018, Breast cancer research : BCR,
W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.
March 2023, International journal of molecular sciences,
W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
October 2018, Clinical breast cancer,
W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.
March 2023, Journal of personalized medicine,
W Zhang, and G X Xu, and J J Li, and X Liu, and Y J Chen, and F Zhang
BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
July 2020, Experimental cell research,
Copied contents to your clipboard!